Menopause, hormone therapy and cardiovascular and cerebrovascular disease

Annals of the Academy of Medicine Singapore

Volumn 37, Issue 1, 2008, Pages 54-62

  Mattar, Citra Nurfarah ^a   Harharah, Lubna ^a   Lin, Lin Su ^a   Agarwal, Anupriya Aditya ^a   Wong, P C ^b   Choolani, Mahesh ^a,b  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Cerebrovascular accident; Hormone replacement therapy; Stroke; Thromboembolism

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; GESTAGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEDROXYPROGESTERONE ACETATE; PLACEBO;

CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFECT; DRUG MECHANISM; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; MEDICAL RECORD REVIEW; MENOPAUSAL SYNDROME; MONOTHERAPY; NONHUMAN; PATIENT CARE; PRACTICE GUIDELINE; REVIEW; STROKE; VENOUS THROMBOEMBOLISM; WOMEN'S HEALTH;

EID: 41149152523     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Stangl V, Baumann G, Stangl K. Coronary atherogenic risk factors in women. Eur Heart J 2002;23:1738-52.
2. Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and the risk of cardiovascular disease: the Framingham Study. Ann Intern Med 1976;85:447-52.
3. Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH. Menopause and the risk of coronary heart disease in women. N Engl J Med 1987;316:1105-10.
4. Stevenson JC, Crook D, Godsland IF. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis 1993;98:83-90.
5. Peters HW, Westendorp IC, Hak AE, Grobbee DE, Stehouwer CD, Hofman A, et al. Menopausal status and risk factors for cardiovascular disease. J Intern Med 1999;246:521-8.
6. Gebara OC, Mittleman MA, Sutherland P, Lipinska I, Matheney T, Xu P, et al. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation 1995;91:1952-8.
7. Scarabin PY, Plu-Bureau G, Bara L, Bonithon-Kopp C, Guize L, Samama MM. Haemostatic variables in menopausal status: influence on hormone replacement therapy. Thromb Haemost 1993;70:584-7.
8. Taddei S, Virdis A, Ghiadoni L, Mattel P, Sudano I, Bernini G, et al. Menopause is associated with endothelial dysfunction in women. Hypertension 1996;28:576-82.
9. Van der Schouw YT, van der Graf Y, Steyerberg EW, Eijkemans MJC, Banga JD. Age at natural menopause as a risk factor for cardiovascular mortality. Lancet 1996;347:714-18.
10. Ossewaarde ME, Bots ML, Verbeek AL, Peeters PH, van der Graaf Y, Grobbee DE, et al. Age at menopause, cause-specific mortality and total life expectancy. Epidemiology 2005;16:556-62.
11. de Kleijn MJ, van der Schouw YT, Verbeek AL, Peeters PH, Banga JD, van der Graaf Y. Endogenous estrogen exposure and cardiovascular mortality risk in postmenopausal women. Am J Epidemiol 2002;155: 339-45.
12. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B. et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335:453-61.
13. Grodstein F, Stampfer MJ, Falkeborn M, Naessen T, Persson I. Postmenopausal hormone therapy and risk of cardiovascular disease and hip fracture in a cohort of Swedish women. Epidemiology 1999;10: 476-80.
14. Grodstein F, Manson JE, Stampfer MJ. Postmenopausal hormone use and secondary prevention of coronary events in the nurses' health study. A prospective, observational study. Ann Intern Med 2001;135:1-8.
15. Grodstein F, Stampfer M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis 1995;38:199-210.
16. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med 1991;325:756-62.
17. Psaty BM, Heckbert SR, Atkins D, Lemaitre R, Koepsell TD, Wahl PW, et al. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med 1994;154:1333-9.
18. Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G, Wu KK, et al. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators. N Engl J Med;328:1069-75.
19. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: the Heart and Estrogen/progestin Replacement Study (HERS) research group. JAMA 1998;289:605-13.
20. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, et al. Cardiovascular disease outcomes during 6.8 years of Hormone Therapy. Heart and Estrogen/Progestin therapy follow-up (HERS II). JAMA 2002;288:49-57.
21. Herrington DM, Vittinghoff E, Lin F, Fong J, Harris F, Hunninghake D, et al. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circulation 2002;105:2962-67.
22. Hodis HN, Mack WJ, Azen SP, Lobo RA, Shoupe D, Mahrer PR, et al. Women's Estrogen-Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial (WELLHART) Research Group: Hormone therapy and the progression of coronary artherosclerosis in post-menopausal women. N Engl J Med 2003;349:535-45.
23. Krasinski K, Spyridopoulos I, Asahara T, van der Zee R, Isner JM, Losordo DW. Estradiol accelerates functional endothelial recovery after arterial injury. Circulation 1997;95:1768-72.
24. Chen SJ, Li H, Durand J, Oparil S, Chen YF. Estrogen reduces myointimal proliferation after balloon injury of rat carotid artery. Circulation 1996;93:577-84.
25. Kushwaha RS, Lewis DS, Carey KD, McGill HC Jr. Effects of estrogen and progesterone on plasma lipoproteins and experimental atherosclerosis in the baboon (Papio sp.). Arterioscler Thromb 1991;11:23-31.
26. Arnal JF, Gourdy P, Elhage R, Garmy-Susini B, Delmas E, Brauchet L, et al. Estrogens and atherosclerosis. Eur J Endocrinol 2004;150:113-7.
27. Haarbo J, Leth-Espensen P, Stender S, Christiansen C. Estrogen monotherapy and combined estrogen-progestogen replacement therapy attenuate aortic accumulation of cholesterol in ovariectomized cholesterol-fed rabbits. J Clin Invest 1991;87:1274-9.
28. Adams MR, Kaplan JR, Manuck SB, Koritnik DR, Parks JS, Wolfe MS, et al. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys: lack of an effect of added progesterone. Arteriosclerosis 1990;10:1051-7.
29. Holm P, Andersen HL, Andersen MR, Erhardtsen E, Stender S. The direct antiatherogenic effect of estrogen is present, absent, or reversed, depending on the state of the arterial endothelium: a time course study in cholesterol-clamped rabbits. Circulation 1999;100:1727-33.
30. Lieberman EH, Gerhard MD, Uehata A, Walsh BW, Selwyn AP, Ganz P, et al. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann Intern Med 1994;121: 936-41.
31. Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343:522-9. Comment in: N Engl J Med 2000;343:572-4; N Engl J Med 2000;343: 1891-2; author reply 1892-3; N Engl J Med 2000;343:1891; author reply 1892-3.
32. Takahashi K, Tanaka E, Murakami M, Mori-Abe A, Kawagoe J, Takata K, et al. Long-term hormone replacement therapy delays the age related progression of carotid intima-media thickness in healthy postmenopausal women. Maturitas 2004;49:170-7.
33. Sumino H, Ichikawa S, Kasama S, Kumakura H, Takayama Y, Sakamaki T, et al. Effect of transdermal hormone replacement therapy on carotid artery wall thickness and levels of vascular inflammatory markers in postmenopausal women. Hypertens Res 2005;28:579-84.
34. Le Gal G, Gourlet V, Hogrel P, Plu-Bureau G, Touboul PJ, Scarabin PY. Hormone replacement therapy use is associated with a lower occurrence of carotid atherosclerotic plaques but not with intima-media thickness progression among postmenopausal women. The vascular aging (EVA) study. Atherosclerosis 2003;166:163-70.
35. [No authors listed] Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial.The Writing Group for the PEPITrial. JAMA 1995;273:199-208. Erratum in: JAMA 1995;274:1676. Comment in: JAMA 1995;274:1675-6. JAMA 1995;274:1675; author reply 1676. JAMA 1995;273:240-1.
36. Haught WH, Mansour M, Rothlein R, Kishimoto TK, Mainolfi EA, Hendricks JB, et al. Alterations in circulating intercellular adhesion molecule-1 and L-selectin: further evidence for chronic inflammation in ischemic heart disease. Am Heart J 1996;132:1-8.
37. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43.
38. Ridker PM, Morrow DA. C-reactive protein, inflammation, and coronary risk. Cardiol Clin 2003;21:315-25.
39. Walsh BW, Cox DA, Sashegyi A, Dean RA, Tracy RP, Anderson PW. Role of tumor necrosis factor-alpha and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women. Am J Cardiol 2001;88:825-8.
40. van Baal WM, Kenemans P, van der Mooren MJ, Kessel H, Emeis JJ, Stehouwer CDA. Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women. Thromb Haemost 1999;81:925-8.
41. Lip GY, Blann AD, Jones AF, Beevers DG. Effects of hormone-replacement therapy on hemostatic factors, lipid factors, and endothelial function in women undergoing surgical menopause: implications for prevention of atherosclerosis. Am Heart J 1997;134:764-71.
42. Seljeflot I, Arnesen H, Hofstad AE, Os I. Reduced expression of endothelial cell markers after long-term transdermal hormone replacement therapy in women with coronary artery disease. Thromb Haemost 2000;83:944-8.
43. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-37.
44. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, et al. Estrogen plus Progestin and the Risk of Coronary Heart Disease. N Engl J Med 2003;349:523-34. Comment in: ACP J Club 2004;140:46; Evid Based Nurs 2004;7:49; N Engl J Med 2003;349:519-21; N Engl J Med 2003;349:521-2.
45. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12.
46. Bush TL. Noncontraceptive estrogen use and risk of cardiovascular disease: an overview and critique of the literature. In: Korenman SG, editor. The Menopause: Biological and Clinical Consequences of Ovarian Failure: Evolution and Management. Norwell, Mass: Serono Symposia, 1990:211-23.
47. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-63.
48. Psaty BM, Heckbert SR, Atkins D, Lemaitre R, Koepsell TD, Wahl PW, et al. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med 1994;154:1333-9.
49. Sidney S, Petitti DB, Quesenberry CP Jr. Myocardial infarction and the use of estrogen and estrogen-progestogen in postmenopausal women. Ann Intern Med 1997;127:501-8.
50. Bush TL, Barrett-Connor E, Cowan LD, Criqui MH, Wallace RB, Suchindran CM, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987;75:1102-9.
51. Sullivan JM, Vander Zwaag R, Hughes JP, Maddock V, Kroetz FW, Ramanathan KB, et al. Estrogen replacement and coronary artery disease. Arch Intern Med 1990;150:2557-62.
52. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991;151:75-8.
53. O'Brien JE, Peterson ED, Keeler GP, Berdan LG, Ohman EM, Faxon DP, et al. Relation between estrogen replacement therapy and restenosis after percutaneous coronary interventions. J Am Coll Cardiol 1996;28:1111-8.
54. Newton KM, LaCroix AZ, McKnight B, Knopp RH, Siscovick DS, Heckbert SR, et al. Estrogen replacement therapy and prognosis after first myocardial infarction. Am J Epidemiol 1997;145:269-77.
55. Sullivan JM, El-Zeky F, Vander Zwaag R, Ramanathan KB. Effect on survival of estrogen replacement therapy after coronary artery bypass grafting. Am J Cardiol 1997;79:847-50.
56. O'Keefe JH, Kim SC, Hall RR, Cochran VC, Lawhorn SL, McCallister BD. Estrogen replacement therapy after coronary angioplasty in women. J Am Coll Cardiol 1997;29:1-5.
57. Cherry N, Gilmour K, Hannaford P, Heagerty A, Khan MA, Kitchener H, et al. ESPRIT team. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet 2002;360:2001-8.
58. Clarke SC, Kelleher J, Lloyd-Jones H, Slack M, Schofiel PM. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study. Br J Obstet Gynaecol 2002;109:1056-62.
59. Adams MR, Kaplan JR, Manuck SB, Koritnik DR, Parks JS, Wolfe MS, et al. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys: lack of an effect of added progesterone. Arteriosclerosis 1990;10:1051-7.
60. Williams JK, Shively CA, Clarkson TB. Determinants of coronary artery reactivity in premenopausal female cynomolgus monkeys with diet-induced atherosclerosis. Circulation 1994;90:983-7.
61. Wolf PA, D'Agostino RB, O'Neal A, Sytkowski P, Kase CS, Belander AJ, et al. Secular trends in stroke incidence and mortality. Stroke 1992;23:1551-5.
62. McEwan BS. Genome and Hormones: Gender differences in physiology. Invited review: estrogens on the brain: multiple sites and molecular mechanisms. J Appl Physiol 2001;91:2785-801.
63. McEwan ES, Alves SH. Estrogen actions in the central nervous system. Endocr Rev 1999;20:279-307.
64. Kimura D. Sex differences in the brain. Sci Am 1992;267:119-25.
65. Paganini-Hill A, Ross RK, Henderson BE. Postmenopausal estrogen treatment and stroke: a prospective study. BMJ 1988;297:519-22.
66. Hunt K, Vessey M, McPherson K. Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis. Br J Obstet Gynaecol 1990;97:1080-6.
67. Finucane FF, Madans JH, Bush TL, Wolf PH, Kleinman JC. Decreased risk of stroke among postmenopausal hormone users: results from a national cohort. Arch Intern Med 1993;153:73-9.
68. Falkeborn M, Persson I, Terent A, Adami HO, Lithell H, Bergstrom R. Hormone replacement therapy and the risk of stroke: follow-up of a population-based cohort in Sweden. Arch Intern Med 1993;153:1201-9.
69. Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, Kooperberg C, Baird A, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: The Women's Health Initiative Memory Study: A randomized controlled trial. JAMA 2003;289:2673-84.
70. Simon JA, Hsia J, Cauley JA, Richards C, Harris F, Fong J, et al. Postmenopausal Hormone Therapy and Risk of Stroke: the Heart and Estrogen-progestin Replacement Study (HERS). Circulation 2001;103:638-42.
71. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A Clinical Trial of Estrogen-Replacement therapy after Ischaemic Stroke. Women's Estrogen for Stroke Trial (WEST). N Engl J Med 2001;345:1243-9.
72. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996;348:977-80.
73. Miller J, Chan BK, Nelson HD. Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2002;136:680-90.
74. Cushman M, Kuller LH, Prentice R, Rodabough RJ, Psaty BM, Stafford RS, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004;292:1573-80.
75. Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, HERS Research Group. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288:58-66.
76. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996;348:977-80.
77. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996;348:981-3.
78. Perez Gutthann S, Garcia Rodriguez LA, Castellsague J, Duque Oliart A. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ 1997;314:796-800.
79. Varas-Lorenzo C, Garcia-Rodriguez LA, Cattaruzzi C, Troncon MG, Agostinis L, Perez-Gutthann S. Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: a population-based study in southern Europe. Am J Epidemiol 1998;147:387-90.
80. Hoibraaten E, Abdelnoor M, Sandset PM. Hormone replacement therapy with estradiol and risk of venous thromboembolism - a population-based case-control study. Thromb Haemost 1999;82:1218-21.
81. Mosca L, Appel LJ, Benjamin EJ, Berra K, Chandra-Strobos N, Fabunmi RP, et al. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation 2004;109:672-93.
82. Scarabin PY, Oger E, Plu-Bureau G. The Estrogen and ThromboEmbolism Risk (ESTHER) study group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003;362:428-32.
83. Royal College of Obstetricians and Gynaecologists [www.rcog.org.uk]. Hormone replacement therapy and venous thromboembolism. Guideline No. 19. Revised January 2004. Available at: http://www.rcog.org.uk/index.asp?PageID=23. Accessed date?
84. Matthews KA, Kuller LH, Wing RR, Meilahn EN, Plantinga P. Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epidemiol 1996;143:971-8.
85. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
86. Rodriguez C, calle EE, Patel AV, Tatham LM, Jacobs EJ, Thun MJ. Effect of body mass on the associaition between estrogen replacement therapy and mortality among elderly US women. Am J Epidemiol 2001;153:145-52.
87. Mosca L, Collins P, Herrington DM, Mendelsohn ME, Pasternak RC, Robertson RM, et al. Hormone therapy and cardiovascular disease: A statement for healthcare professionals from the American heart association. Circulation 2001;104:499-503.